Kura Oncology Inc.

7.05
-0.09 (-1.26%)
At close: Mar 28, 2025, 3:59 PM
7.00
-0.71%
After-hours: Mar 28, 2025, 07:48 PM EDT

Kura Oncology Statistics

Share Statistics

Kura Oncology has 80.75M shares outstanding. The number of shares has increased by 2.14% in one year.

Shares Outstanding 80.75M
Shares Change (YoY) 2.14%
Shares Change (QoQ) 1.47%
Owned by Institutions (%) 90.77%
Shares Floating 75.15M
Failed to Deliver (FTD) Shares 469
FTD / Avg. Volume 0.03%

Short Selling Information

The latest short interest is 8.14M, so 10.47% of the outstanding shares have been sold short.

Short Interest 8.14M
Short % of Shares Out 10.47%
Short % of Float 12.48%
Short Ratio (days to cover) 4.6

Valuation Ratios

The PE ratio is -4.31 and the forward PE ratio is -4.2. Kura Oncology's PEG ratio is 1.5.

PE Ratio -4.31
Forward PE -4.2
PS Ratio 13.93
Forward PS 0.8
PB Ratio 1.81
P/FCF Ratio 5.61
PEG Ratio 1.5
Financial Ratio History

Enterprise Valuation

Kura Oncology Inc. has an Enterprise Value (EV) of 1.03B.

EV / Earnings -5.94
EV / Sales 19.17
EV / EBITDA -6.09
EV / EBIT -5.35
EV / FCF 7.72

Financial Position

The company has a current ratio of 9.46, with a Debt / Equity ratio of 0.04.

Current Ratio 9.46
Quick Ratio 9.46
Debt / Equity 0.04
Total Debt / Capitalization 3.86
Cash Flow / Debt 8.09
Interest Coverage -119.33

Financial Efficiency

Return on equity (ROE) is -0.42% and return on capital (ROIC) is -45.43%.

Return on Equity (ROE) -0.42%
Return on Assets (ROA) -0.23%
Return on Capital (ROIC) -45.43%
Revenue Per Employee $280,640.62
Profits Per Employee $-906,161.46
Employee Count 192
Asset Turnover 0.07
Inventory Turnover n/a

Taxes

Income Tax 2.02M
Effective Tax Rate -0.01

Stock Price Statistics

The stock price has increased by -66.95% in the last 52 weeks. The beta is 0.84, so Kura Oncology's price volatility has been higher than the market average.

Beta 0.84
52-Week Price Change -66.95%
50-Day Moving Average 7.8
200-Day Moving Average 14.75
Relative Strength Index (RSI) 39.74
Average Volume (20 Days) 1.48M

Income Statement

In the last 12 months, Kura Oncology had revenue of 53.88M and earned -173.98M in profits. Earnings per share was -2.02.

Revenue 53.88M
Gross Profit 53.88M
Operating Income -193.19M
Net Income -173.98M
EBITDA -169.5M
EBIT -193.19M
Earnings Per Share (EPS) -2.02
Full Income Statement

Balance Sheet

The company has 224.46M in cash and 16.59M in debt, giving a net cash position of 207.87M.

Cash & Cash Equivalents 224.46M
Total Debt 16.59M
Net Cash 207.87M
Retained Earnings -895.42M
Total Assets 760.16M
Working Capital 666.12M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 134.32M and capital expenditures -472K, giving a free cash flow of 133.84M.

Operating Cash Flow 134.32M
Capital Expenditures -472K
Free Cash Flow 133.84M
FCF Per Share 1.55
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -358.55% and -322.89%.

Gross Margin 100%
Operating Margin -358.55%
Pretax Margin -319.15%
Profit Margin -322.89%
EBITDA Margin -314.57%
EBIT Margin -358.55%
FCF Margin 248.4%

Dividends & Yields

KURA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -28.65%
FCF Yield 23.51%
Dividend Details

Analyst Forecast

The average price target for KURA is $28, which is 297.2% higher than the current price. The consensus rating is "Buy".

Price Target $28
Price Target Difference 297.2%
Analyst Consensus Buy
Analyst Count 10
Stock Forecasts

Scores

Altman Z-Score -0.3
Piotroski F-Score 5